Page 1 of 2


 


ASSIGNMENT


 


Whereas, I, David Koos an individual residing in La Mesa, CA, referred to herein as ASSIGNOR, has
invented new and useful innovations described in:


 


U.S. Provisional Application No. 63/120,673, entitled: CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC
AGENT IN COMBINATION WITH A BIOACTIVE IMMUNOSTIMULATORY AGENT, filed on December 2nd, 2020;


 


herein to as the “Invention”;


 


And Whereas, Entest BioMedical Inc., a California corporation, located at 4700 Spring St., Suite 304,
La Mesa, CA, 91942 herein referred to as ASSIGNEE, desires to acquire the entire right, title, and interest in and to the
said Invention,


 


Now therefore, for good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, ASSIGNOR hereby acknowledges that they have sold, assigned, transferred, and set over, and by these
presents do hereby sell, assign, and transfer, and set over unto ASSIGNEE and its successors and assigns, 100% of the following:


 


(A) ASSIGNOR’S right, title and interest in and to the Invention;


 


(B) any domestic, foreign, or reissue patents that claim priority to U.S. Provisional Application No. 63/120,673,


 


(C) any continuations, continuations-in-part, substitutes, or divisional applications, foreign or
domestic, that claim priority U.S. Provisional Application No. 63/120,673;


 


ASSIGNOR authorized and requests the Commissioner for Patents to issue any resulting patent(s) as
follows: 0% to ASSIGNOR and 100% to ASSIGNEE.


 






    	 	1	 



     


    

 


Page 2 of 2


 


ASSIGNOR hereby further sells, assigns, transfers and sets over unto ASSIGNEE, 100% of ASSIGNOR’S
entire right, title, and interest in and to said invention in the Unites States and every country foreign to the United
States. ASSIGNOR agrees to execute all papers, five any required testimony, and perform other lawful acts,
at ASSIGNEE’S expense, as ASSIGNEE may require to enable ASSIGNEE to perfect ASSIGNEE’s interest in any
resulting patent of the United State and countries foreign thereto, and to acquire, hold, enforce, convey, and uphold
validity of said patent and reissues and extensions thereof, and ASSIGNEE’S interest therein.


 


In testimony whereof ASSIGNOR intending to be legally bound hereunto affix their signatures.


 


ASSIGNOR


 





	/s/ David Koos	 	12/2/2020
	(David Koos)	 	(Date)



 


 



    	 	2	 



     


    

 


ASSIGNMENT


 


Page 1 of 2


 


Whereas,  Entest BioMedical Inc., a California corporation, located at 4700 Spring St., Suite 304,
La Mesa, CA, 91942, referred to herein as ASSIGNOR, is the owner of new and useful innovations described in:


 


U.S. Provisional Application No. 63/120,673, entitled: CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC
AGENT IN COMBINATION WITH A BIOACTIVE IMMUNOSTIMULATORY AGENT, filed on December 2nd, 2020; and


 


U.S. Provisional Application No. 61/253,934, entitled: CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC
AGENT IN COMBINATION WITH A BIOACTIVE IMMUNOSTIMULATORY AGENT, filed on October 22nd, 2009;


 


herein collectively referred to as the “Invention”;


 


And Whereas, Sybleu Inc., a Wyoming corporation, located at 109 East 17th Street, Suite 460, Cheyenne,
Wyoming, 82001, herein referred to as ASSIGNEE, desires to acquire the entire right, title, and interest in and to the said
Invention,


 


Now therefore, for good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, ASSIGNOR hereby acknowledges that they have sold, assigned, transferred, and set over, and by these
presents do hereby sell, assign, and transfer, and set over unto ASSIGNEE and its successors and assigns, 100% of the following:


 


(A) ASSIGNOR’S right, title and interest in and to the Invention;


 


(B) any domestic, foreign, or reissue patents that claim priority to U.S. Provisional Application No.
63/120,673 and U.S. Provisional Application No. 61/253,934,


 



    	 	3	 



     


    

 


Page 2 of 2





 


(C) any continuations, continuations-in-part, substitutes, or divisional applications, foreign or
domestic, that claim priority U.S. Provisional Application No. 63/120,673 and U.S. Provisional Application No. 61/253,934;


 


ASSIGNOR authorized and requests the Commissioner for Patents to issue any resulting patent(s) as follows:
0% to ASSIGNOR and 100% to ASSIGNEE. 


 


ASSIGNOR hereby further sells, assigns, transfers and sets over unto ASSIGNEE, 100% of ASSIGNOR’S
entire right, title, and interest in and to said invention in the Unites States and every country foreign to the United
States. ASSIGNOR agrees to execute all papers, five any required testimony, and perform other lawful acts,
at ASSIGNEE’S expense, as ASSIGNEE may require to enable ASSIGNEE to perfect ASSIGNEE’s interest in any
resulting patent of the United State and countries foreign thereto, and to acquire, hold, enforce, convey, and uphold
validity of said patent and reissues and extensions thereof, and ASSIGNEE’S interest therein.


 


In testimony whereof ASSIGNOR intending to be legally bound hereunto affix their signatures.


 


ASSIGNOR


 





	/s/ David Koos	 	12/2/2020
	(David Koos)	 	(Date)
	 	 	 
	CEO of Entest BioMedical Inc.	 	 
	 	 	 



 






    	 	4